Phase 2 results on patients that developed PRCA with EPO should open door for rapid approval in non-dialysis patients with PRCA as an orphan indication by changing the perspective on the benefit-risk profile.
Thanks Pharmalot. PRCA is a pretty rare condition though, isn't it? I understand that approval for that is pretty much a foregone conclusion since Omontys doesn't bring it on and it is far more serious than any treatment side effects. I was talking about the situation for 'normal' non dialisys anemia patients in need of epo or similar.